中国肺癌杂志2025，Vol.28Issue(11)：857-865,9.DOI:10.3779/j.issn.1009-3419.2025.101.19
肺癌免疫检查点抑制剂相关肺炎的危险因素、分子机制及多模态预警策略
Risk Factors,Molecular Mechanisms,and Multimodal Early Warning Strategies for Immune Checkpoint Inhibitor-associated Pneumonitis in Lung Cancer
摘要
Abstract
In recent years,immune checkpoint inhibitors(ICIs),as a revolutionary therapeutic approach in oncolo-gy,have demonstrated remarkable clinical efficacy across various malignant tumors.With the widespread clinical application of ICIs,their associated toxicities have emerged as a critical issue that urgently requires resolution in the field of cancer immuno-therapy.ICIs-associated pneumonitis(CIP)specifically refers to immune-related adverse events(irAEs)of the lung induced by ICIs therapy,the underlying pathogenesis of which remains incompletely elucidated.As a rare yet severe complication of ICIs treatment,and CIP is characterized by insidious onset,rapid progression,poor prognosis,and high mortality rate,with highly heterogeneous clinical manifestations and radiological features.Due to the lack of specific biomarkers and objective diagnostic indicators,the early identification and diagnosis of CIP present significant clinical challenges.By reviewing previous literature and studies,this paper summarizes recent advances in understanding the clinical manifestations,risk factors,potential molecu-lar mechanisms,biomarkers,and early warning systems of CIP in patients receiving immunotherapy for lung cancer.The aim of this article is to provide a reference for the clinical management of CIP and offer a theoretical basis for establishing an early screening and precision diagnosis and treatment system for this condition.关键词
肺肿瘤/免疫检查点抑制剂相关肺炎/危险因素/分子机制/早期预警机制Key words
Lung neoplasms/Immune checkpoint inhibitor-associated pneumonitis/Risk factors/Molecular mechanism/Early warning mechanism引用本文复制引用
詹举蓉,陈秀迪,李娜..肺癌免疫检查点抑制剂相关肺炎的危险因素、分子机制及多模态预警策略[J].中国肺癌杂志,2025,28(11):857-865,9.基金项目
This paper was supported by the grants from Research on the Prevention and Treatment of Cancer,Cardio-vascular and Cerebrovascular,Respiratory,and Metabolic Diseases-National Science and Technology Major Project(No.2023ZD0506104,No.2023ZD0506100)and Chongqing Natural Science Foundation(No.CSTB2022NSCQ-MSX0127)(All to Na LI). 本文受癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项(No.2023ZD0506104,No.2023ZD0506100)和重庆市自然科学基金项目(No.CSTB2022NSCQ-MSX0127)资助 （No.2023ZD0506104,No.2023ZD0506100）
